New
HealthMore in Health→
Intranasal Sufentanil-Ketamine Shows Fast Relief for Pediatric Acute Pain
Key Takeaways
- A phase 2/3 study of 152 children aged 1 to under 18 found that a fixed-dose intranasal sufentanil-ketamine formulation rapidly reduced moderate-to-severe acute pain in the emergency department.
- At 15 minutes, 54 percent of participants had a pain intensity score of 4 or lower; by 30 minutes, 88 percent did, and 86.2 percent achieved at least a 50 percent reduction from baseline.
- No severe adverse events were reported; 49.7 percent had at least one adverse event, 94 percent of which were mild, and median sedation scores stayed at 0 or 1.
- Median treatment satisfaction was 5 out of 5 with 92 percent acceptability across all age groups.
DE
DT Editorial Team··via medicalxpress.com